Roberto Tamma1, Monica Rutigliano2, Giuseppe Lucarelli2, Tiziana Annese1, Simona Ruggieri1, Eliano Cascardi3, Anna Napoli3, Michele Battaglia2, Domenico Ribatti4. 1. Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy. 2. Department of Emergency and Organ Transplantation-Urology, Andrology and Kidney Transplantation Unit, University of Bari Medical School, Bari, Italy. 3. Department of Emergency and Organ Transplantation-Section of Pathology, University of Bari Medical School, Bari, Italy. 4. Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy. Electronic address: domenico.ribatti@uniba.it.
Abstract
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) represents a highly vascularized aggressive kidney cancer. Due to ccRCC chemotherapy resistance, antiangiogenesis is one of the most innovative targeted therapies for this tumor. The tumor microenvironment exerts important roles in tumor growth, angiogenesis, and metastatic escape. MATERIALS AND METHODS: In this study, we investigated the composition of tumor cell microenvironment including mast cells, macrophages, and microvascular density in ccRCC tumor tissues collected from patients who underwent nephrectomy treated or not with bevacizumab as neoadjuvant therapy before surgery. RESULTS: The results of this study indicate that bevacizumab-treated ccRCC samples present reduced microvascular density as well as a lower number of CD68-positive macrophages and tryptase-positive mast cells in comparison with the untreated patients. CONCLUSIONS: It follows that the antiangiogenic activity of bevacizumab may be due to a direct effect on angiogenic cytokines released by tumor cells and an indirect effect on the release of pro-angiogenic factors by inflammatory stromal cells.
BACKGROUND:Clear cell renal cell carcinoma (ccRCC) represents a highly vascularized aggressive kidney cancer. Due to ccRCC chemotherapy resistance, antiangiogenesis is one of the most innovative targeted therapies for this tumor. The tumor microenvironment exerts important roles in tumor growth, angiogenesis, and metastatic escape. MATERIALS AND METHODS: In this study, we investigated the composition of tumor cell microenvironment including mast cells, macrophages, and microvascular density in ccRCC tumor tissues collected from patients who underwent nephrectomy treated or not with bevacizumab as neoadjuvant therapy before surgery. RESULTS: The results of this study indicate that bevacizumab-treated ccRCC samples present reduced microvascular density as well as a lower number of CD68-positive macrophages and tryptase-positive mast cells in comparison with the untreated patients. CONCLUSIONS: It follows that the antiangiogenic activity of bevacizumab may be due to a direct effect on angiogenic cytokines released by tumor cells and an indirect effect on the release of pro-angiogenic factors by inflammatory stromal cells.
Authors: Marcela García; Maria Belen Palma; Jerome Verine; Santiago Miriuka; Ana M Inda; Ana L Errecalde; François Desgrandchamps; Edgardo D Carosella; Diana Tronik-Le Roux Journal: BMC Cancer Date: 2020-07-03 Impact factor: 4.430